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Expression Constructs
The native Sulfolobus solfataricus HerA and NurA were amplified from S. solfataricus P2 gDNA, and cloned as described previously (1). Point mutations in the herA and nurA ORFs were introduced using site-directed mutagenesis (QuikChange, Stratagene) and were confirmed by DNA sequencing of the complete open reading frame. The K154A HerA clone was prepared as described previously (1), the M51E, M56E, I61E, L65E, R142A, R381A, K363A, D471A and G465STOP HerA were produced by site-directed mutagenesis using the oligonucleotides listed below: 
Generation of the HerAm10 mutant used for the crystallization of the HerA hexamer
Initial crystals of the wtHerA:AMP-PNP complex were found to diffract poorly, despite repeated rounds of optimisation. An effort to improve crystal diffraction was therefore made, making use of two protein engineering approaches that were ultimately combined.
In early protein purification trials, it was noted that a small fraction of the wtHerA protein appeared to be truncated at two points, which may have been contributing to poor crystal diffraction. Edman degradation analyses of these minor contaminants revealed that these shorter expression products started at either M51 or M82. The proximity of these to the protein N-terminus suggested that the truncations were the result of alternate start codons. Protein alignments confirmed that these could be safely mutated from methionines to leucines; individual mutation via site-directed mutagenesis (QuikChange, Stratagene; see Supplementary Table 1 ) resulted in single removal of each respective 'truncation' upon protein expression, while double mutation resulted in complete removal of both alternate start contaminants. This latter HerAM2 construct was expressed and resultant protein was found to bind to wtNurA as per wtHerA (data not shown).
In a second engineering approach, an effort was made to remove high entropy surface residues from the HerA sequence. This made use of the Surface Entropy Reduction prediction (SERp) server at UCLA (2) to identify sites most suitable for mutation. Suggested site clusters were manually pruned to protect key conserved regions. The remaining six clusters were then individually mutated to alanines by site-directed mutagenesis (QuikChange, Stratagene; see Supplementary Table 1) , expressed and purified. Of the six clusters investigated, two (Cluster4 and Cluster5) were found to be important for protein stability and DNA binding (data not shown); these were therefore removed from further analysis. Mutation of the remaining four clusters (1, 2, 3 and 6) was then performed sequentially to generate a single construct harbouring a total of 8 single amino acid substitutions; the encoded protein (HerAm8) was again expressed and purified to ensure stability.
Finally, the two engineering approaches were combined to generate HerAm10, a construct encoding a surface entropy-reduced protein with two M>L mutations near the N-terminus. The encoded protein was used throughout crystallization trials.
Protein purification
Native, untagged S. solfataricus HerA and NurA proteins were expressed in Rosetta (DE3) pLysS cells (Novagen) E. coli cells, as described previously (1). The mutant HerA proteins used in this study were purified in the same manner. Briefly, cells were grown at 37 °C to an OD 600 = 0.3, temperature lowered to 25 °C, induced with 0.3 mM IPTG and grown over-night with shaking. Cells were harvested by centrifugation, resuspended in 2 X TBS (200 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol, 1 mM DTT) and lysed by sonication, in the presence of EDTA-free protease inhibitors (cOmplete cocktailRoche). Insoluble material was removed via centrifugation (20 000 g for 10 mins at 4°C). The soluble fraction was subsequently heated to 70 °C (for HerA) or 60 °C (for NurA) for 20 minutes and centrifuged (20 000 g for 10 mins at 4°C), and then passed through a 0.4 micron filter to remove insoluble material. For NurA, the soluble, heat-treated, fraction was loaded onto a HiTrap heparin, column (GE biosciences) pre-equilibrated with 50 mls Low Salt Buffer (50 mM NaCl, 200 mM Tris pH 8.0, 5 % glycerol, 1 mM DTT). For HerA, the soluble, heat treated fraction was diluted with Buffer A (200 mM Tris pH 8.0, 5% glycerol, 1 mM DTT), reducing the NaCl concentration to 100 mM before loading onto a HiTrap HP column (GE Healthcare). The proteins were eluted from the heparin column with a gradient of 50-1000 mM NaCl, in 20 mM Tris pH 8.0, 300 mM NaCl, 5% glycerol, 1 mM DTT. HerA eluted at approximately 300 mM NaCl and NurA at 360 mM NaCl. Fractions containing the purified proteins were pooled and concentrated before running a final size-exclusion purification step over a Superdex 200 16/600 column (GE Healthcare), in 20 mM Tris [pH 8.0], 300 mM NaCl, 5 % glycerol, 1 mM DTT. Fractions containing the purified proteins were pooled, concentrated, aliquoted and flash frozen in liquid N 2 . Protein concentrations were quantified by UV spectrophotometry.
Crystallization of HerAm10:AMP-PNP
All crystals of HerAm10:AMP-PNP used in this study were obtained using pre-formed HerAm10:NurA complex. To generate the complex, individual components were mixed together with a 10% excess of NurA (assuming a 6:2 HerA:NurA ratio) and heated for 20 minutes at 60 °C, before being applied to a Superdex 200 10/300 GL gel filtration column (GE Healthcare) pre-equilibrated in protein buffer (see below). Following size exclusion chromatography, elution fractions corresponding to purified HerAm10:NurA complex were pooled and concentrated to ~7 mg/ml. Concentrated complex was then supplemented with 3 mM AMP-PNP and heated again at 60 °C for 10 minutes. Both native and selenomethionine-containing crystals of HerAm10:AMP-PNP were subsequently grown using the vapour diffusion method by mixing equal volumes of HerAm10:NurA:AMP-PNP mixture and respective crystallization buffer (see below). Resultant 2 l drops were sealed against a 1ml well of the crystallization buffer and allowed to equilibrate at 19 C. Suitable crystals were transferred to a cryoprotection buffer (see below) and subsequently snap-frozen in liquid nitrogen.
To generate initial electron density maps from experimental phases, HerAm10:NurA complex was generated using selenomethionine-derivatised HerAm10 protein (SeMetHerAm10). Crystals of SeMetHerAm10:AMP-PNP were obtained using high-salt protein buffer (20 mM Tris-HCl pH 8, 10% v/v glycerol, 300 mM NaCl, 10 mM DTT) and SeMet crystallization buffer (0.2 M tri-methylamine Noxide, 0.1 M Tris-HCl pH 8.9, 22% w/v PEG 2K MME). Crystals were observed as clusters within 7 days. Single crystals were carefully separated from these clusters and transferred to SeMet cryoprotection buffer (0.2 M tri-methylamine N-oxide, 0.1 M Tris-HCl pH 9, 22% w/v PEG 2K MME, 26% v/v Ethylene glycol) before freezing. X-ray diffraction data from a single crystal were collected at beamline ID14-4 of the European Synchrotron Radiation Facility (ESRF) at 90 K. Data were collected at two wavelengths corresponding to peak and inflection points of the Se K edge -see Supplementary  Table 2 . Data extending to 3.4 Å were initially processed using XDS (3) via the xdsme scripts of Pierre Legrand (https://code.google.com/p/xdsme/). Scaling and merging was subsequently performed using SCALA (4). PHENIX (5) was used to generate an initial electron density map via the multiple anomalous diffraction (MAD) method. The map was sufficient to place most secondary structure elements with some uncertainty in registry. The resulting partial model was therefore used for molecular replacement in a native data set.
To generate high resolution data, native crystals of HerAm10:AMP-PNP were obtained using low-salt protein buffer (20 mM Tris-HCl pH 8, 150 mM NaCl) and native crystallization buffer (20% v/v glycerol ethoxylate, 12.5% v/v tetrahydrofuran, 100 mM Tris-HCl pH 8). Crystals were observed within 7 days and transferred to native cryoprotection buffer (20% v/v glycerol ethoxylate, 9% v/v tetrahydrofuran, 50 mM Tris-HCl pH 8, 25% v/v glycerol) before freezing. X-ray diffraction data from a single crystal were collected at beamline IO2 of the Diamond Light Source at 90 K -see Supplementary Table 2 . Data extending to ~2.85 Å were initially processed using XDS (3) via the xdsme scripts of Pierre Legrand (https://code.google.com/p/xdsme/). PHASER (6) was used within the PHENIX package (5) to solve the structure by molecular replacement, using the partial MAD structure as a search model. Crystallographic refinement was carried out using phenix.refine (7) together with manual model rebuilding in Coot (8) .
Iterative rounds of refinement and rebuilding were carried out to complete the structure to final R and R free values of 0.2112% and 0.2541% respectively. The final crystallographic model contains two HerA chains in the asymmetric unit, 922 residues, 113 water molecules, 2 magnesium ions and 2 AMP-PNP ligands. 96.5% of residues are in the favoured regions of the Ramachandran plot and there are no outliers. The Molprobity score is 1.42 (100 th percentile).
Combined HerA-NurA DNA unwinding and nuclease (DNA degradation) reactions DNA unwinding and nuclease reactions, using the HerA-NurA complex, were performed in a 40 μl reaction volume containing 20 mM Tris (pH 8), 5% glycerol, 5 mM MnCl 2 , 100 mM NaCl, 3 mM ATP, 1 mM DTT and 1 X BSA (NEB). 2.5 μM (hexamer) HerA (native protein, or K154A, R142A, R381A, K363A, or D471A mutants) and 2.5 μM (dimer) native NurA were preincubated at 60°C for 20 mins in 20 μl of the reaction buffer, in the absence of DNA, before cooling to room temperature. 160 ng of a 5.3 kb dsDNA PCR product, in 20 μl of the reaction buffer, was then added at room temperature (1.25 nM final DNA concentration in the 40 μl final volume). Reactions were then incubated at 60°C and terminated on ice at 5, 10, 20 or 40 minute time-points. Following addition of 0.5% SDS, and 2 mg.ml -1 proteinase K (for 2 h at 37°C), the reactions were incubated for 4 hours at 37°C to remove the HerA and NurA proteins. After addition of 8 μl 6 X glycerol loading buffer (30% glycerol, 20mM Tris (pH 8), 0.25% bromophenol blue and 0.6% SDS), 15 μl of the reactions were then run on a 0.8% agarose gel, in 1 X TBE, at 2.65 V.cm -1 for 3.5 hours. The DNA was visualized by staining with ethidium bromide. The data were quantified using the ImageQuant software (GE Healthcare), and plotted with the 'ProFit' software (www.quansoft.com).
The DNA substrate used in these assays was a 5.3 kb PCR product amplified from φX174 plasmid DNA (RFI -circular, double-stranded DNA, covalently closed. NEB) with the primers PhiXfor (GAGTTTTATC GCTTCCATGACGCAGAAG) and PhiX5300rev (TGAGCAGATTTGTCGTCACAGGTTGCGC), using Herculase polymerase (Abgene).
DNA unwinding (helicase) reactions
DNA unwinding reactions, using the D58A nuclease inactive NurA protein (1), were performed in a 20 μl reaction volume containing 20 mM Tris acetate (pH 8), 50 mM potassium acetate, 10 mM magnesium acetate, 1 mM dithiothreitol (DTT), 5% glycerol, 100 mM NaCl, 5 mM MgCl 2 , 3 mM ATP, 0.1 mg.ml -1 BSA]. 0.5 μM of hexameric HerA protein (native protein, or K154A, R142A, R381A, K363A, or D471A mutants) and 0.5 μM dimeric D58A NurA protein were preincubated at 60°C for 20 mins before addition of a 10 nM 32 P-labelled double-stranded DNA substrate and incubated at 60°C for 30 mins. Reactions were terminated by the addition of 20 μl stop buffer (100 mM EDTA, 0.5% SDS, 0.1% bromophenol blue and 50% glycerol) and separated on 12% SDS-PAGE in 1x TBE, 0.2% SDS at 7.5 Vcm -1 . Gels were dried and results were visualised by phosphoimaging (GE Healthcare Typhoon system). The data were quantified using the ImageQuant software (GE Healthcare), and plotted with the 'ProFit' software (www.quansoft.com).
The radiolabelled DNA substrate used in these assays was a 54 nucleotide duplex, with a 25 nucleotide 5' single-stranded overhang, formed by annealing the two oligonucleotides 5PRIFOR (AATTGTGATCTCTTCTCCTTGTCAACAGTTAAATCATATGTTGAATTGAAAATAAATAAAT ACTTTATATGATTTGTAC) and BLUNTREV (GTACAAATCATATAAAGTATTTATTTATTTTCAATTCAACATATGATTTAACTG) (1). Prior to annealing the duplex, the BLUNTREV oligonucleotide was radiolabelled as follows: 100 ng oligonucleotide DNA substrate (4.1 pmol) was 5' end labeled with 50 pmol [γ-32 P] ATP (Perkin Elmer) using 20 units of T4 Polynucleotide Kinase (NEB). This was then annealed to a two fold molar excess of the unlabeled 5PRIFOR complementary oligonucleotide. Unincorporated radionucleotide was removed using a G25 microspin column (GE Healthcare) and annealed substrates were further purified using non-denaturing PAGE.
Size exclusion chromatography (analytical gel filtration)
Physical interactions between HerA (native protein or M(L)51E, M56E, I61E or L65E mutant) and native NurA were investigated by size exclusion chromatography. HerA (0.9 nM, hexamer) and a twofold excess of NurA (1.8 nmol, dimer) were mixed and pre-incubated at 60°C for 20 minutes in a total of 350 μl gel filtration buffer (20 mM Tris [pH 8.0], 300 mM NaCl, 5% glycerol, 1 mM DTT). Reactions were subsequently spun at 13 000g in a benchtop centrifuge for 5 min to remove any precipitated material, and loaded on Superdex S200 HR 10/300 size exclusion chromatography column (GE Healthcare). 0.5 ml fractions were collected and resolved by SDS-PAGE, on 15% polyacrylamide gels. The proteins were visualized with Coomassie stain.
Triplex displacement assays
Triplex displacement assays were based on the method of Firman and Szczelkun (9) but used a linearised form of plasmid. SwaI was used to linearised pLKS5, positioning the 22 bp triplex forming oligo (TFO) centrally within the 7500 bp vector. The TFO was end labeled with γ-32 P using polynucleotide kinase. Triplexes were formed as previously described (9) . WT or mutant HerA and nuclease inactivated (D58A) NurA complex was formed by pre-incubating the proteins in reaction buffer (25 mM MES, 50 mM NaCl, 10 mM MgCl 2 , 0.5 mM spermidine and 3 mM ATP, pH 5.5) at 60°C for 30 min and then cooled to 50°C. 5 nM triplex was added and incubated at 50°C for appropriate time. Reactions were terminated by cooling on ice and addition of 6 X glycerol loading buffer (30% glycerol, 20 mM Tris [pH 8], 0.25% bromophenol blue and 0.6% SDS). Products were resolved on 1% agarose gels in 40 mM tris-acetate, 5 mM sodium acetate, 1 mM MgCl 2 , pH 5.5 buffer at 120 V for 2.5 h at 4°C. Agarose gels were dried in the following manner. Gels were placed face down on a piece of Saran wrap with the following placed on top: a single piece of DE81 paper, three sheets of Whatman paper and a stack of paper tissues. A glass plate was placed on top of this assembly and weighted down with a 2 l bottle filled with water and left for 1 hour at room temperature. After blotting the stack of paper tissues and Whatman paper were discarded and the partially dried gel, sandwiched between DE81 paper and saran wrap was inverted and transferred to a vacuum drier (DE81 paper placed on surface of gel drier) and dried for another hour under vacuum at 80°C. After gel drying the results were analysed by phosphoimaging (Typhoon system and ImageQuant software, GE Healthcare).
ATPase assays
ATP turnover was determined as previously described (1) with the following minor changes. Reactions were performed in 200 l aliquots in a buffer containing 20 mM Tris-HCl (pH8), 100 mM NaCl, 5% v/v glycerol, 5 mM MgCl 2 , 400 M ATP, 400 nM DNA (where relevant) and 30 nM HerA:D58ANurA complex (assuming 6:2 ratio HerA monomer : D58ANurA monomer). Before addition to reactions, HerA:NurA complex was pre-formed by mixing individual components (at 360 nM HerA hexamer / NurA dimer) and incubating for 20 minutes at 60 C. DNA substrates are listed in Supplementary  Table 2 . The duplex DNA species were generated by annealing ATPBluntFwd (CGTTGACAGTCACCTCTTACATTCCTCAACTGGACTGACG) and ATPBluntRev (CGTCAGTCCAGTTGAGGAATGTAAGAGGTGACTGTCAACG) (blunt substrate), or ATP5PFwd (TTTTTTTTTTTTTTTCGTTGACAGTCACCTCTTACATTCCTCAACTGGACTGACG) and ATP5PRev (TTTTTTTTTTTTTTTCGTCAGTCCAGTTGAGGAATGTAAGAGGTGACTGTCAACG) (5 overhang substrate), or ATP3PFwd (CGTTGACAGTCACCTCTTACATTCCTCAACTGGACTGACGTTTTTTTTTTTTTTT) and ATP3PRev (CGTCAGTCCAGTTGAGGAATGTAAGAGGTGACTGTCAACGTTTTTTTTTTTTTTT) (3 overhang substrate). Assays were performed three times.
Helicase complementation assays (mutant doping assays)
Native and catalytically inactivated (K154A) HerA were mixed together at the described ratios (from 0 to 50% K154A mutant, in 2% increments), at a total final concentration of 0.5 μM hexamer. The proteins were incubated at 60°C for 20 minutes, to permit the formation of mosaic hexamers. 0.5 μM dimeric D58A (nuclease inactivated) NurA was then added and the reaction incubated for a further 20 minutes to allow the formation of the HerA-NurA complex. 0.5 μM of the resultant HerA/D58A NurA (hexamer/dimer) complex was then added to 10 nM of the 32 P-labelled double-stranded DNA substrate used in the helicase unwinding assay and incubated at 60 °C for 30 mins. The radiolabelled DNA substrate used in these assays was the same 54 nucleotide duplex, with a 25 nucleotide 5' singlestranded overhang, that was used in the earlier helicase assays, formed by annealing the same two oligonucleotides 5PRIFOR and BLUNTREV (as described above). Additionally, the data presented in Supplementary Figure 6 confirm that mixing wild-type and mutant HerA proteins resulted in the formation of hybrid hexameric rings. These data were fitted to a first order exponential decay model using 'ProFit' software (www.quansoft.com).
